188 related articles for article (PubMed ID: 38865670)
21. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibition in Cancer: An Update on Clinical Development.
Sachdev E; Tabatabai R; Roy V; Rimel BJ; Mita MM
Target Oncol; 2019 Dec; 14(6):657-679. PubMed ID: 31625002
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
[TBL] [Abstract][Full Text] [Related]
24. Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Kholmanskikh Van Criekingen O; Koole S; Thomas DM; Gelderblom H
Cancer Cell; 2024 Jun; 42(6):923-929. PubMed ID: 38861927
[TBL] [Abstract][Full Text] [Related]
25. In Silico Discovery of Novel Flavonoids as Poly ADP Ribose Polymerase (PARP) Inhibitors.
Shah A; Parmar G; Seth AK
Curr Comput Aided Drug Des; 2021; 17(3):344-350. PubMed ID: 32268868
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
29. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown JS; O'Carrigan B; Jackson SP; Yap TA
Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
[TBL] [Abstract][Full Text] [Related]
30. Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Dias MP; Moser SC; Ganesan S; Jonkers J
Nat Rev Clin Oncol; 2021 Dec; 18(12):773-791. PubMed ID: 34285417
[TBL] [Abstract][Full Text] [Related]
31. Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.
Thein KZ; Thawani R; Kummar S
Cancer Treat Res; 2023; 186():143-170. PubMed ID: 37978135
[TBL] [Abstract][Full Text] [Related]
32. Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models.
Ordway GA; Szebeni A; Hernandez LJ; Crawford JD; Szebeni K; Chandley MJ; Burgess KC; Miller C; Bakkalbasi E; Brown RW
Int J Neuropsychopharmacol; 2017 Dec; 20(12):994-1004. PubMed ID: 29016792
[TBL] [Abstract][Full Text] [Related]
33. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
34. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
35. PARP inhibitor pick-me-up.
Mullard A
Nat Rev Drug Discov; 2019 Oct; 18(11):814. PubMed ID: 31673138
[No Abstract] [Full Text] [Related]
36. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
37. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
38. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
Xu Y; Wu H; Huang L; Zhai B; Li X; Xu S; Wu X; Zhu Q; Xu Q
Eur J Med Chem; 2022 Jul; 237():114417. PubMed ID: 35504210
[TBL] [Abstract][Full Text] [Related]
39. Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
Buege M; Mahajan PB
Rev Recent Clin Trials; 2015; 10(4):326-39. PubMed ID: 26374559
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors: enhancing efficacy through rational combinations.
Bhamidipati D; Haro-Silerio JI; Yap TA; Ngoi N
Br J Cancer; 2023 Oct; 129(6):904-916. PubMed ID: 37430137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]